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Abstract: The Predictive Safety Testing Consortium (PSTC) is one of nine consortia comprising the Critical Path 
Institute (C-Path), a non-profit organisation launched in 2005 and dedicated to playing the role of a catalyst in the 
development of new approaches that advance medical innovation and regulatory science. C-Path achieves this by lead-
ing teams that share data, knowledge and expertise resulting in sound, consensus-based science. PSTC is a unique, 
public-private partnership that brings pharmaceutical companies together to share and validate safety testing methods 
under the advisement of worldwide regulatory agencies, including the US Food and Drug Administration (FDA), the 
European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The 
eighteen corporate members of PSTC share a common goal: to find improved safety testing methods and approaches 
utilizing fluid-based safety biomarkers which accurately predict drug-induced tissue injury. Specifically, the primary 
goal of PSTC is the qualification of novel translational safety biomarkers for use in early clinical trials in order to ena-
ble safer investigations and development of new drug candidates. This manuscript describes the critical importance of 
improved safety biomarkers to the drug development process and the present state of the biomarker qualification 
process with regulatory agencies. In addition, the work that the PSTC and its collaborative partners have done and con-
tinue to do to identify and qualify more selective and specific safety biomarkers is highlighted. Finally, successes in-
cluding the recently adopted regulatory Letter of Support and ongoing efforts to better define the regulatory qualifica-
tion process and an integrated translational safety strategy are also discussed. 
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1. Safety Biomarkers 
any academic and pharmaceutical industry 
scientists are currently involved in the dis-
covery and biological validation of a multi-
tude of novel biomarkers[1]. These biomarkers are in-
tended to determine whether a patient is susceptible to 
a disease, already has a disease, or the extent to which 
a disease has progressed. In addition, biomarkers can  
be used to determine whether a patient is responding 
to a treatment, is experiencing adverse side effects 
related to the treatment, or whether a treatment has 
worked. 
While much of the data generated for these novel 
biomarkers will be published in the open literature, the 
proof required to obtain regulatory biomarker qualifi-
cation, i.e. the demonstration of both the scientific 
utility and regulatory reliability of biomarkers in drug 
M 
John-Michael Sauer, Elizabeth G Walker and Amy C Porter 
 
 Journal of Medicines Development Sciences (2015)–Volume 1, Issue 1 35 
development, is significantly higher than what is re-
quired for peer reviewed publication. The qualifica-
tion of biomarkers is analogous to obtaining market-
ing authorisation for a drug product or device in that 
there are high scientific and regulatory expectations. 
However, that is where the comparison ends. The 
same evidentiary standards applied to drug develop-
ment cannot be applied to biomarker qualification, as 
the ultimate scientific goal is very different.  
In addition, the relationship of the stakeholders in 
biomarker qualification is very different to the rela-
tionship of those in drug development. When a drug 
candidate receives formal regulatory approval and is 
marketed, the drug developer stands to reap the finan-
cial rewards associated with a successful product, 
while the health authority takes on the potential for 
additional risk to public health regardless of the finan-
cial success of the drug. However, drug developers, 
regulators and the general public benefit when a bio-
marker or other drug development tool (DDT) is suc-
cessfully qualified, by virtue of the accelerated 
process and improved probability of developing effi-
cacious and safe drugs through use of the biomarker. 
Thus, the relationship between DDT qualification 
submitters and health authorities has to be a collabora-
tive relationship and differs significantly from a single 
company investing in a drug development program. 
Of course, during the scientific review of qualification 
data supporting a novel biomarker or DDT, the regu-
latory agencies retain their objective and independent 
assessment. But all stakeholders must invest in dis-
cussion around the appropriate study design, data 
analysis, and level of evidence necessary to support 
the proposed use of a novel biomarker. The precompe-
titive collaborative consortia models currently being 
applied in the biomarker space have created these 
unique, collaborative relationships across health au-
thorities, pharmaceutical companies, academia, and 
patient groups. This concept has allowed for the shar-
ing of costs, risks and benefits necessary for the suc-
cessful qualification of biomarkers. 
The characterization and qualification of clinical 
safety biomarkers is a prototypical example of the 
benefits of this collaborative relationship. Insufficient 
therapeutic index is a major cause of candidate attri-
tion in drug development. The lack of appropriate 
prediction of safety liabilities results in unforeseen 
adverse events in clinical trials or the unwarranted 
abandonment of potentially safe and effective thera-
pies. Throughout the drug discovery process, thera-
peutic and toxic exposures are determined, and clini-
cal safety biomarkers are essential for maximizing 
therapeutic index/clinical safety in several ways. For 
example, safety biomarkers can be applied to address 
candidate selection and manage risk by monitoring the 
no-observed-adverse-effect levels of exposure in prec-
linical and clinical studies. Safety biomarkers are also 
useful for assessing the human relevance of preclinical 
safety findings and enabling the development of safe 
or safer dosing paradigms. In nonclinical studies, tar-
get organ toxicity is assessed using histopathological 
analysis. However, in clinical trials, histopathological 
analysis is rarely available and biomarkers are critical 
to assess potential target tissue toxicity in humans. 
Thus, the most impactful safety biomarkers will be 
those used in clinical trials with direct translational 
ties to nonclinical safety studies.  
Several consortia, primarily driven by pharmaceut-
ical industry members and encouraged by health au-
thorities, have been formed to evaluate and qualify 
safety biomarkers for use in early clinical drug devel-
opment trials. In the remainder of this manuscript, we 
will focus on the safety biomarker qualification efforts 
of the Critical Path Institute’s (C-Path) Predictive 
Safety Testing Consortium (PSTC), as well as the PSTC 
collaborations with the Foundation for the National 
Institutes of Health’s Biomarkers Consortium’s (FNIH 
BC) Kidney Safety Project (KSP) and the Innovative 
Medicines Initiative’s (IMI) Safer and Faster Evid-
ence-based Translation Consortium (SAFE-T). Both 
of these collaborations are driven by the common goal 
of modernizing safety science through the qualifica-
tion of clinical safety biomarkers for use in drug de-
velopment.  
2. Qualification of Safety Biomarkers 
Qualification is a formal regulatory review and 
acceptance process at the US Food and Drug 
Administration (FDA) and the European Medicines 
Agency (EMA) whereby a conclusion is reached such 
that within the stated context of use (COU), a 
biomarker or other drug development tool or novel 
methodology can be used with regulatory certainty. 
Regulatory certainty is defined as the assurance to 
drug developers that these approaches will be 
accepted by regulatory authorities. A COU is analog-
ous to a registered drug’s label. According to the FDA, 
a COU is a comprehensive and clear statement that 
describes the manner of use, interpretation, and pur-
pose of use of a biomarker in drug development[2]. A 
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hypothetical COU is shown below. This COU has 
been proposed by the PSTC’s Skeletal Myopathy 
Working Group (SKMWG) in response to discussions 
around how an ideal novel safety biomarker for 
drug-induced skeletal muscle injury could be most 
useful in drug development. 
An example COU for novel safety biomarkers for 
skeletal muscle injury: 
The qualified biomarker(s) may be used to moni-
tor for skeletal muscle safety in early clinical 
studies with new molecular entities (NMEs) that 
have been shown to cause skeletal muscle injury 
in animal toxicology studies. Ideally, the quali-
fied biomarker(s) will also be translatable and 
will show a change in animal studies that can 
monitored and then used to inform skeletal mus-
cle safety in clinical studies. The qualified 
biomarker(s) will be used in conjunction with 
conventional markers of skeletal muscle injury 
(e.g. serum creatine kinase (CK) activity) as a 
more sensitive and/or earlier biomarker of 
skeletal muscle injury. When a biomarker level 
greatly differs from a defined threshold, as seen 
in the absence (or presence) of an elevation of 
serum CK activity, this would be considered an 
indicator of skeletal muscle injury. For NMEs 
with skeletal muscle pathology in animal toxi-
cology studies, applying the biomarker(s) in the 
design of the initial single and multiple ascend-
ing dose studies would enable safer progression 
in clinical development. Use of the biomarker(s) 
could also enable or restrict the planned dose 
escalation to higher clinical exposures, depend-
ing on risk-benefit considerations. This is be-
cause the new biomarker(s) would detect skeletal 
muscle injury earlier and therefore increase 
confidence in escalating clinical exposures up to 
or exceeding the nonclinical no-observed-ad-
verse-effect level (NOAEL), provided that no 
change in concentration of biomarker(s) is seen 
in the clinical study. The absence of a significant 
change in the biomarker(s) in single and multiple 
ascending dose studies in healthy volunteers 
would signify no clinically relevant skeletal mus-
cle injury at those exposures. 
Regulatory qualification at FDA and EMA gen-
erally consists of a consultation and advice phase, 
followed by a review phase. In the case of the EMA, 
the process for Scientific Advice and Opinion is uti-
lised to give Qualification Advice and Opinion. Qua-
lification, on a fundamental level involves a submitter 
articulating a COU for a novel DDT or methodology 
which adds significant value to some aspect of drug 
development, and compiling the scientific data and 
evidence in support of that specific COU.  
Following qualification, a guidance document on 
the uses and limitations of the biomarker, including 
the COU, is issued by the FDA and EMA. It is impor-
tant to point out that the strategy for safety biomarker 
qualification utilises a translational approach. Al-
though the primary data for clinical qualification are 
the biomarker performance data from clinical studies, 
nonclinical data are used to underpin the clinical data 
and anchor the biomarker’s response to a defined his-
topathological change. A positive qualification deci-
sion by regulatory authorities ensures a more efficient 
implementation of safety biomarkers and encourages 
researchers to utilise these biomarkers in the drug de-
velopment process. Thus, qualification results in both 
increased scientific acceptance and regulatory cer-
tainty based on a weight of evidence argument. Quali-
fied safety biomarkers should provide a clear and ea-
sily measurable indication of organ injury, giving all 
parties involved a standardised, reliable tool.  
3. Letter of Support for Safety Biomarkers 
The Letter of Support was established by the FDA and 
EMA in 2014 as a means to recognise the potential 
utility of exploratory biomarkers prior to qualification. 
C-Path’s PSTC was the first biomarker submitter to 
receive a Letter of Support from the FDA and the 
EMA. The Letter of Support, as a regulatory outcome, 
resulted in part from the discussion between PSTC, 
EMA and FDA, and the realization that greater 
attention to promising biomarker programs would 
help facilitate the use of exploratory biomarkers. 
The FDA has stated that the Letter of Support is an 
opportunity to recognise the potential utility of explo-
ratory biomarkers prior to qualification[3]. A Letter of 
Support is issued from the FDA to a submitter who 
has assembled the necessary information about prom-
ising biomarkers. The letter briefly describes the 
views of the FDA’s Center for Drug Evaluation and 
Research (CDER) on the potential value of a bio-
marker and encourages further evaluation of the bio-
marker. This letter does not connote qualification of a 
biomarker. It is meant to enhance the visibility of the 
biomarker, encourage data sharing, and stimulate ad-
ditional studies on promising biomarkers which are 
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not yet ready for qualification. The FDA’s Letter of 
Support encourages the identification and qualifica-
tion of new DDTs and has been recognised as an 
approach to overcome hurdles in drug development 
programs with the potential to enhance the availability 
of useful information about drug safety and efficacy.  
The EMA has stated that based on qualification 
advice, the Agency may propose a Letter of Support as 
an option, when the novel methodology under evalua-
tion cannot yet be clinically qualified but is shown to 
be promising based on preliminary data[4]. A Letter of 
Support from the EMA aims to encourage data sharing 
and to facilitate studies supporting eventual qualifica-
tion for the novel methodology under evaluation. 
These letters from the EMA include a high-level 
summary of the novel methodology, COU, available 
data, and ongoing and future investigations. Like the 
FDA, the EMA publishes Letters of Support on their 
website, in agreement with sponsors. 
In each case where both the FDA and EMA have 
granted Letters of Support to PSTC, the intent of the 
letter, as well as the basic language has been similar. 
However, although the goal of the Letter of Support 
mechanism is similar for both, the mechanism and 
regulatory infrastructure utilised to issue such letters 
differs. For the EMA, the Letter of Support is an 
integrated part of qualification and a result of 
qualification advice, while the FDA sees the Letter of 
Support as a product outside of the qualification 
process, although it may also be issued for a project 
pursuing qualification. While the final outcome may 
be the same, the process and program expectations to 
garner a Letter of Support are not identical between 
the FDA and EMA. 
Regardless of its positioning, the Letter of Support 
is a significant step forward in helping to drive the 
qualification of exploratory biomarkers. This relative-
ly straightforward approach has created numerous 
opportunities to share data from nonclinical and clini-
cal studies utilising exploratory biomarkers. For 
example, a broad data set from an exploratory clinical 
biomarker with a supporting nonclinical data set could 
result in the qualification of the biomarker, while 
dedicated prospective qualification studies or other 
approaches could be used to expand the COU for a 
given biomarker. To this end, it is essential that a cen-
tralised database be established where anonymized 
biomarker data from global academic and indus-
try-sponsored trials can be collected, maintained, 
shared and analysed. This could result not only in the 
qualification of biomarkers, but could also enable 
COU optimization, and identify the impact of such 
interventions on drug safety. 
In order to help drug development sponsors under-
stand the value of including exploratory biomarkers in 
nonclinical studies and clinical trials, the PSTC has 
posted summary data packages on each of the bio-
markers that have received a Letter of Support on the 
C-Path website[5]. 
4. Critical Path Institute’s Predictive Safety 
Testing Consortium 
The PSTC is one of nine consortia comprising C-Path, 
a non-profit organisation launched in 2005 and dedi-
cated to playing the role of a catalyst in the develop-
ment of new approaches that advance medical innova-
tion and regulatory science. This is achieved by lead-
ing teams that share data, knowledge and expertise, 
resulting in sound, consensus-based science. Although 
C-Path has a number of funding models for its consor-
tia, PSTC is funded by a grant from the FDA’s Center 
for Federal Drug Administration and Industry Colla-
boration (CFIC) and members’ contributions. Mem-
bers’ contributions consist of a membership fee and 
in-kind contributions that support the research re-
quired to drive the objectives of PSTC’s working 
groups. PSTC is a unique, public-private partnership 
that brings pharmaceutical companies together to 
share and validate safety testing methods under the 
advisement of worldwide regulatory agencies, includ-
ing the FDA, the EMA, and the Japanese Pharmaceu-
ticals and Medical Devices Agency (PMDA)[6–9] 
(Figure 1). All eighteen corporate members of PSTC 
share a common goal: to find improved safety testing 
methods and approaches utilizing fluid-based safety 
biomarkers to accurately predict drug-induced tissue 
injury (Figure 2). Specifically, the primary goal of 
PSTC is the qualification of novel translational safety 
biomarkers for use in early clinical drug development 
trials in order to enable the safer investigation and 
development of new drug candidates. 
As discussed above, clinical safety biomarkers for 
use in early drug development trials are critically im-
portant because insufficient therapeutic index is a ma-
jor cause of new drug failure. However, current bio-
marker standards for many drug-induced tissue inju-
ries either do not exist or have significant limitations. 
Thus, there is a clear need for improved safety bio-
markers for each of the target organs under investiga-
tion by the PSTC. PSTC’s working groups are structured  
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Figure 1. PSTC collaborative structure[10]. 
 
 
 
Figure 2. Monitoring drug-induced tissue injury using fluid 
biomarkers. 
 
around target organs, including heart, liver, skeletal 
muscle, vasculature, kidney and testis, with cross- 
functional teams working through common appro-
aches such as microRNA analysis, assessment and 
categorization of pathological lesions, and approaches 
to statistical analysis. Currently there are six working 
groups in PSTC and a brief description of their objec-
tives is provided below. 
4.1 Nephrotoxicity Working Group (NWG) 
Conventional biomarkers of drug-induced kidney in-
jury (DIKI) currently used in drug development lack 
sensitivity. The loss of kidney function that defines 
acute kidney injury (AKI) is most often detected by 
measurement of serum creatinine, which is slow to 
respond even in cases of severe kidney injury. Thus, 
there is a clear need for biomarkers that detect early 
DIKI to enable earlier intervention. The NWG, in 
collaboration with the FNIH BC KSP and the IMI 
SAFE-T DIKI work package, is working towards the 
clinical qualification of several urinary kidney safety 
biomarkers including osteopontin, clusterin, cystatin C, 
kidney injury molecule-1, N-acetyl-beta-D-glucosam-
inidase, neutrophil gelatinase-associated lipocalin, 
total protein, and albumin. PSTC has already demon-
strated the diagnostic utility of these biomarkers in 
rodents[11–25], and has an active research program in 
canines and nonhuman primates.  
4.2 Skeletal Myopathy Working Group (SKMWG) 
Drug-induced skeletal muscle toxicity is becoming 
more prevalent as an issue in drug development likely 
due to the evaluation of novel pharmacological targets 
and the disease populations being investigated. As-
partate aminotransferase activity (AST) and creatine 
kinase (CK; serum CK activity), the traditional bio-
markers of skeletal muscle toxicity, lack both specific-
ity and sensitivity. Novel skeletal muscle biomarkers 
show promise as more sensitive and more specific 
biomarkers of drug-induced skeletal muscle injury. 
The SKMWG is working towards the clinical qualifi-
cation of several skeletal muscle safety biomarkers 
including plasma/serum skeletal troponin I, myosin 
light chain 3, fatty acid-binding protein 3, and creatine 
kinase muscle type. It is hoped that these biomarkers 
will provide greater predictive accuracy in the diagno-
sis and monitoring of drug-induced skeletal muscle 
toxicity in drug development clinical trials[26,27]. 
4.3 Hepatotoxicity Working Group (HWG) 
Standard biomarkers of drug-induced liver injury 
(DILI) utilised by the clinical community for many 
years include alanine aminotransferase (ALT) and 
AST. However, both the specificity and sensitivity of 
these markers are limited due to lack of correlation 
between changes in these liver enzymes and observa-
ble histopathological damage. Although these trans-
aminases have proven to be excellent markers of he-
patotoxicity, additional biomarkers that more fully 
inform prediction of DILI are desirable. For instance, 
new markers that help predict whether ALT increases 
will resolve or progress to more serious DILI, and 
markers that can better discriminate liver and skeletal 
muscle injury will help in the complex assessment of 
DILI in drug development. The HWG, in collabora-
tion with the SAFE-T DILI work package, is working 
towards the clinical qualification of several liver safe-
ty biomarkers including plasma/serum miR-122, glu-
tamate dehydrogenase, arginase, sorbitol dehydroge-
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nase and glutathione-S-transferase. Another objective 
of the HWG’s work has been to understand the 
potential hepatotoxic liability of drug candidates that 
are potent inhibitors of the bile salt export pump (BSEP) 
and devise strategies to mitigate the potential risk. The 
PSTC hopes to clarify several aspects associated with 
DILI which is an important, complex issue in drug 
development.  
4.4 Vascular Injury Working Group (VIWG) 
Currently, there are no biomarkers available to detect 
drug-induced vascular injury (DIVI) in humans. The 
VIWG in collaboration with the SAFE-T DIVI work 
package is characterizing several biomarkers that are 
diagnostic for inflammation, as well as endothelial cell 
and smooth muscle cell injury in nonclinical species 
and humans with the ultimate goal of qualifying these 
biomarkers for use in drug development. Although 
this group has successfully identified candidate bio-
markers, differences in protein expression and func-
tion across humans and animals have limited the di-
rect translation of these safety biomarkers. The 
qualification of DIVI biomarkers represents a 
challenge greater than that faced by other working 
groups due to the lack of a current clinical gold 
standard biomarker and the lack of direct translation 
of the clinical biomarkers being pursued[28]. 
4.5 Testicular Toxicity Working Group (TWG) 
There are no biomarkers available for detecting 
drug-induced seminiferous tubule toxicity in the clinic, 
highlighting the value of work being done by the TWG. 
Currently, this group is focusing on the applicability 
of microRNA species as biomarkers of testicular in-
jury. A focused research plan has been implemented 
with the ultimate goal of achieving clinical qualifica-
tion of testicular safety biomarkers. The program is 
currently in the early discovery stage, working thro-
ugh much of the basic science associated with reliably 
quantifying microRNA in serum. Although this pro-
ject’s goal of providing biomarkers for drug-induced 
testicular injury is of significant value, the basic re-
search around the quantification of microRNA-based 
biomarkers will also impact other biomarker discovery 
and qualification efforts. 
4.6 Cardiac Hypertrophy Working Group (CHWG) 
Work is being completed by the CHWG to evaluate 
NT-proANP in rodents as a marker of drug-induced 
hemodynamic stress which leads to changes in cardiac 
mass. The data collected indicates that NT-proANP 
can be used as a screening tool to identify clinical 
candidates with cardiac hypertrophy liabilities without 
resorting to ECG-gated magnetic resonance imaging 
(MRI) in nonclinical studies. Although NT-proANP 
may not be a candidate for biomarker qualification, 
the results of this work will have a fundamental im-
pact on approaches used in investigational toxicology. 
This work points out one of the PSTC goals beyond 
regulatory endorsement: to impact the pharmaceutical 
industry’s approach to toxicology (safety) in both drug 
discovery and development[29,30]. 
4.7 PSTC Regulatory Successes 
Despite considerable advances in medicine and tech-
nology, many of the approaches and strategies used to 
evaluate drug safety have not changed in decades. The 
ultimate goal of the PSTC is to transform the current 
approach to drug safety testing and liaise with 
regulatory authorities to offer assurance to drug 
developers that these approaches will be accepted by 
regulatory authorities and thereby improve both the 
speed and precision of the drug development process. 
The PSTC has been successful in pursuit of this goal 
through the qualification of novel translational safety 
biomarkers. 
In 2008, PSTC engaged in a joint process between 
the FDA and EMA to achieve the qualification of a 
biomarker. Utilizing this joint process, seven rodent 
kidney safety biomarkers were qualified by both 
agencies[11,12]. In 2010, these same kidney biomarkers 
were also qualified with Japan’s PMDA[13]. Following 
this series of qualifications, as additional biomarker 
qualification requests entered the consultation (i.e. 
Qualification Advice at EMA) phase, the regulatory 
expectations for evidentiary standards evolved. This 
resulted in a general bottleneck in the qualification 
process. Therefore, for the past several years the 
PSTC has been working with the FDA and EMA to 
better define the requirements within the qualification 
process. An important initial step was the piloting of a 
mechanism by which regulatory authorities could 
recognise the potential utility of exploratory biomark-
ers prior to qualification, known as the Letter of Sup-
port. In 2014, the PSTC NWG received a Letter of 
Support from the FDA and EMA for two new kidney 
safety biomarkers[14,15]. And in 2015, the PSTC 
SKMWG received a Letter of Support for four new 
skeletal muscle injury biomarkers[26,27]. The Letter of 
Support represents a significant accomplishment in 
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the regulatory authorities’ armamentarium and has 
been compatible with PSTC’s goal to assure all 
stakeholders greater clarity in the path to qualification. 
In addition, the Letter of Support opens the door to the 
potential for new opportunities via broader generation 
of use data to further impact the qualification process. 
5. Predictive Safety Testing Consortium and its 
Key Collaborations 
No single company or research organisation can inde-
pendently change the approach to safety science. Thus, 
collaboration in pre-competitive consortia like PSTC 
is an effective approach to impact the scientific and 
regulatory landscape that governs drug development. 
The large number of consortia actively involved in 
addressing gaps in the science and practice of drug 
development, creates the opportunity to collaborate 
based on common objectives. However, it is interest-
ing that although consortia are founded on the spirit of 
collaboration, cross-consortium collaborations are rare. 
A fundamental obstacle to collaboration appears to be 
“self-preservation” and the fear of losing relevance or 
advantage over rivals, resulting in the demise of the 
consortium, or the desire to be the first consortium to 
succeed. Luckily, in some cases the benefit of colla-
boration outweighs the imagined liabilities, and strong 
leaders find common ground to achieve even larger 
objectives. Although it is likely that cross-consortium 
collaborations will continue to expand and become the 
accepted norm, the establishment of functional rela-
tionships between collaborative groups can be limited 
by legal, logistical and cultural factors. Therefore, it is 
paramount that consortia organisers envision crucial 
collaborations at the project design stage and establish 
a collaborative framework at project inception.  
By pooling resources and combining efforts, PSTC 
is working to improve the safety of newly-created 
therapies thereby expediting drug development and 
the regulatory approval process. This will have a posi-
tive, measurable impact on all stakeholders, including 
pharmaceutical companies, regulatory authorities and 
patients. Cross-consortium collaboration provides the 
resources to radically impact safety science in the 
short term. For example, while focused on nonclinical 
and translational aspects of safety biomarker qualifi-
cation, in some cases PSTC lacks the clinical expertise 
required for efficient clinical qualification of transla-
tional biomarkers. Therefore, in order to achieve their 
primary goal of qualifying safety biomarkers, PSTC 
has partnered with two important consortia, FNIH BC 
KSP and the IMI SAFE-T. 
The PSTC collaborations with FNIH BC KSP and 
IMI SAFE-T are productive collaborations between 
consortia which share overlapping goals, as well as 
corporate members, in this case from the pharmaceut-
ical industry. PSTC signed formal collaboration 
agreements with FNIH BC KSP on October 25, 2011 
and with IMI SAFE-T on May 23, 2013. Although 
FNIH and SAFE-T have had a less formal relationship, 
PSTC’s involvement with both consortia has helped 
enable the sharing of regulatory strategy and scientific 
approaches between these two groups. The following 
sections will discuss the collaborations that PSTC has 
established with the FNIH BC KSP and SAFE-T. 
5.1 Foundation for the National Institutes of 
Health’s Biomarkers Consortia Kidney Safety 
Project (FNIH BC KSP) 
FNIH was created by the United States Congress with 
the purpose of supporting the National Institutes of 
Health (NIH) in its mission and advancing collabora-
tion between the NIH and biomedical researchers 
from universities, industry and not-for-profit organisa-
tions. To that end, since 1996, FNIH has raised over 
$800 million and supported over 500 projects includ-
ing research partnerships, scientific education and 
training, conferences, events and other scientific pro-
grams. One of the FNIH programs, the FNIH BC has 
a mission similar to that of the PSTC which is to the 
foster the exchange of knowledge and expertise 
among industry, academic and government leaders to 
qualify biomarkers for diagnosing disease, predicting 
therapeutic response and improving clinical practice. 
PSTC and the FNIH BC KSP initiated a formal 
collaboration on October 25, 2011. This $4 million, 
4-year project includes representatives from C-Path/ 
PSTC, the pharmaceutical industry, academia, and 
government agencies. The project is intended to adv-
ance the acceptance of biomarkers designed to detect 
DIKI in clinical trials. The ultimate goal of the project 
is to identify novel biomarkers that are more sensitive 
than standard approaches and establish better criteria 
for when kidney safety concerns indicate the need to 
halt further testing of a drug in humans. This work 
represents the next logical step in the translational 
application of the rodent kidney safety biomarkers 
previously qualified by the PSTC[11–13]. These project 
objectives are being accomplished through the con-
duct of retrospective and prospective clinical study 
analyses. The learning phase portion of the project has 
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been completed and two prospective clinical studies 
are ongoing in patients who are currently being treated 
with cisplatin for head and neck cancer or tobramycin 
for cystic fibrosis with the intention of qualifying 
biomarkers of DIKI. The specific DIKI biomarkers 
include urinary osteopontin, clusterin, cystatin C, 
kidney injury molecule-1, N-acetyl-beta-D-glucosam-
inidase, neutrophil gelatinase-associated lipocalin, total 
protein, and albumin.  
PSTC has supported the FNIH BC KSP through fi-
nancial and in-kind contributions. For example, PSTC 
has conducted a clinical study in healthy volunteers to 
aid in the selection of appropriate urinary biomarkers 
and to define the baseline values of the novel bio-
markers in a representative Phase 1 population. With 
the support of C-Path’s internal Submission Readiness 
Review Team (SRRT), PSTC is also responsible for 
all regulatory submissions and liaising with both the 
FDA and EMA in support of this joint project. C-Path, 
with its significant experience in data handling, sto-
rage and analysis has also implemented a nonclinical 
and clinical biomarker database for the program as 
part of its broader data platform. The ultimate goal of 
the project is to garner regulatory qualification of the 
new biomarkers in order to give confidence to drug 
developers that the use of these biomarkers will be 
accepted in regulatory submissions for new drugs. To 
this end, two qualification approaches are moving 
forward in parallel. In the first approach, data from the 
learning phase and urinary biomarker data from the 
clinical study in healthy volunteers and a cohort of 
mesothelioma patients treated with cisplatin are being 
used to derive a composite measure designed to 
monitor subjects for DIKI on a cohort basis in Phase 1 
clinical trials. In the second approach, data from the 
two prospective studies and learning phase data will 
be used to support an expanded COU for the kidney 
safety biomarkers. 
5.2 Innovative Medicines Initiative’s (IMI) Safer 
and Faster Evidence-based Translation Consor-
tium (SAFE-T)  
IMI was launched in 2008 as part of the European 
Technology Platform on Innovative Medicines that 
was supported under the European Commission's Sixth 
Framework Programme for Research as a gathering of 
stakeholders, led by the pharmaceutical industry. IMI 
is a partnership between the European Union (represe-
nted by the European Commission) and the European 
pharmaceutical industry (represented by EFPIA, the 
European Federation of Pharmaceutical Industries and 
Associations). IMI is working to improve health by 
speeding up the development of and patients’ access to 
innovative medicines, particularly in areas where there 
is an unmet medical or social need. It does this by fa-
cilitating collaboration between the key players in-
volved in healthcare research, including universities, 
the pharmaceutical and other industries, small and 
medium-sized enterprises, patient organisations, and 
medicines regulators. By the end of 2013, IMI had 
released eleven calls for proposals and committed its 
entire €2 billion budget. The success of IMI prompted 
the European Commission and EFPIA to take steps to 
continue IMI under Horizon 2020, the European 
Commission’s framework program for research and 
innovation that runs from 2014 to 2020. The legisla-
tion creating ‘IMI 2’ was approved by the European 
Parliament and Member States in the first half of 2014, 
and IMI 2 was officially launched in July 2014. IMI 2 
will run from 2014 to the end of 2024 and it will have 
a total budget of up to €3.276 billion. 
IMI’s SAFE-T consortium, initiated in 2010, is a 
public-private partnership that brings together phar-
maceutical companies, universities, hospitals and bio-
technology companies to share and validate each oth-
er’s safety testing methods. With 25 cooperating con-
sortium members, the goal of the SAFE-T consortium 
is to generate enough clinical evidence for qualifying 
new safety biomarkers for regulatory decision-making. 
SAFE-T is working to address a major hurdle in drug 
development: the current lack of sensitive and specific 
clinical tests to diagnose and monitor DIKI, DILI and 
DIVI in humans. New biomarker tests will enable stu-
dies to assess whether these drugs are safe to ‘translate’ 
into clinical use. Furthermore, the new translational 
safety biomarkers will allow the identification and 
management of side effects of drugs throughout de-
velopment, helping to reduce the risk associated with 
developing medicines and improving the safety man-
agement of patients. 
With common members and goals, the PSTC has 
worked closely with SAFE-T from its inception, in-
itiating a formal collaboration on May 23, 2013 to 
work together in their efforts to improve drug safety 
for three organs in need of better clinical monitoring, 
including kidney, liver and the vascular system[31]. 
The ultimate goal of this collaboration is to identify 
biomarkers for monitoring DIKI, DILI and DIVI and 
qualify the biomarkers with regulatory authorities. 
The PSTC provides the nonclinical and translational 
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underpinning to each of the qualification efforts with-
in SAFE-T. Although this collaboration has only been 
formalised for approximately two years, the PSTC has 
refocused its relevant working groups to support 
SAFE-T’s efforts. The benefits of the PSTC and 
SAFE-T collaboration include cost sharing/cost reduc-
tion, greater speed/efficiency and sharing of the com-
plementary strengths of the two organisations. For 
example, by leveraging the PSTC efforts in nonclini-
cal studies, the clinical biomarkers being advanced by 
SAFE-T are adequately anchored by nonclinical 
translational data. The PSTC and SAFE-T partnership 
has also increased scientific influence and awareness 
through joint communication efforts and coordinated 
submission of new biomarker data for review by reg-
ulatory authorities. Generation of a more robust data-
set with more rapid dissemination to the clinical com-
munity and patient groups in the US and Europe will 
also be possible with the coordinated resources of 
both consortia, ultimately increasing the likelihood of 
acceptance and application of these novel safety bio-
markers for DIKI, DILI and DIVI. 
6. Advancing the Qualification Process and 
Defining Evidentiary Standards 
As previously stated, insufficient therapeutic index is 
a major cause of failure in drug development and be-
cause many current safety biomarkers lack sufficient 
sensitivity and specificity to adequately evaluate the 
therapeutic index of new drugs, there is a critical need 
for improved safety biomarkers. However, the adop-
tion of novel safety biomarkers through the qualifica-
tion process has been slowed for two major reasons: 
(1) the regulatory and scientific expectations for qua-
lification have been evolving as more experience is 
gained from this relatively new program and (2) the 
inaccessibility of data from those using the biomarkers 
due to concerns over maintaining a competitive ad-
vantage and conservative legal positions around drug 
safety liability. Clearly defined evidentiary standards 
and access to appropriate data will dramatically acce-
lerate the qualification of safety biomarkers[32]. 
The articulation of evidentiary standards will allow 
biomarker submitters to appropriately plan their quali-
fication strategies, and have more direct conversations 
with the FDA and EMA with the understanding that 
the level of evidence for qualification of a biomarker 
is directly related to factors such as the breadth of the 
stated COU, the implications for risk to patients if the 
biomarker “fails”, and the predictability of the assay 
performance characteristics. At this point the obvious 
evidentiary gaps include:  
(i) Defined expectations around clinical data gener-
ation and prospective analysis, 
(ii) Statistical methodology expectations for con-
firmatory data analysis, 
(iii) Biomarker assay validation and performance 
expectations, 
(iv) Nonclinical data expectation for (translational) 
qualification of clinical safety biomarkers. 
The path to developing regulatory guidance on 
evidentiary standards for qualification of biomarkers 
will require involvement of all sectors of the bios-
cience research community including but not neces-
sarily limited to industry, FDA, EMA, government 
research entities, academia, patient groups and non- 
profit organisations. As with the drug development 
and regulatory review processes, there will be a need 
for regulatory guidance documents focused on pro-
viding direction for critical elements of the overall 
biomarker qualification process. For example, there 
might be a guidance document specific to statistical 
methodology for biomarker qualification or one de-
scribing assay validation. This will be an iterative 
process that seeks to refine terminology, standards, 
language etc., in parallel with incorporating lessons 
learned from ongoing biomarker qualification pro-
grams. This will require science-based discussions 
without attribution to enable an open dialogue with 
exchange of various expert perspectives. Those with 
specific expertise in current biomarker qualification, 
drug development, device development, clinical trial 
design, statistical methodology, analytic methodology, 
regulatory process and strategy, regulatory deci-
sion-making, data handling, data sharing and database 
methodology must be included in order to ensure that 
information contributing to the framework for regula-
tory expectations and eventual guidance documents 
represents the application of scientific methods on the 
way to a regulatory outcome. Ultimately, with the at-
tention of stakeholders, this process will provide the 
required underpinning to expedite the qualification of 
biomarkers and other DDT’s and methodologies. 
Several key aspects should be considered in creat-
ing scientific expectations specific to qualification of 
safety biomarkers. A brief list of considerations is 
presented below for safety biomarkers that are sup-
ported by both translational nonclinical data and clin-
ical trial data. 
(i) Availability of sufficiently validated analytical 
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assays to quantify biomarkers, 
(ii) Biological understanding of the biomarker in-
cluding the specificity of the response to toxicological 
outcomes in the target tissue and other relevant tissues 
as well as the pharmacologic effects of agents without 
toxicity in the target organ, 
(iii) Understanding of mechanism of the biomark-
er’s biological response, 
(iv) Correlation of biomarker response to pathology 
and improved performance relative to other (standard) 
biomarkers, 
(v) Consistent response across mechanistically dif-
ferent compounds with similar response; similar re-
sponse across sex, strain, and species, 
(vi) Presence of dose-response and temporal rela-
tionship to the magnitude of response.  
The second issue slowing adoption of novel safety 
biomarkers is inaccessibility to data from those using 
the biomarkers. Therefore, multiple approaches should 
be considered to encourage drug development spon-
sors and academic centres to: (1) capture data accord-
ing to pre-determined standards so that data sets 
across multiple contributors can be aggregated and (2) 
share data through a protected mechanism in order to 
advance understanding of biomarker performance and 
contribute to robust decision-making about the regu-
latory acceptance of that biomarker. An approach be-
ing considered by C-Path is a proof-of-concept expe-
riment whereby data from use of a pre-specified set of 
biomarkers can be housed in a central data repository 
held by a neutral, third party for the purpose of ad-
vancing the accumulation of needed evidence to ena-
ble regulatory decision about the biomarkers. This 
experiment should demonstrate the value of a more 
collaborative approach that will expedite the timeline 
to achieving qualification of new biomarkers. 
Finally, it is critical to identify the quickest path to 
qualification and the implementation of safety bio-
markers in well-controlled clinical trials, because the 
only way to understand the advantages and disadvantag-
es of a biomarker will be through its broad application. 
7. Defining an Integrated Translational Safety 
Strategy 
At this point it is clear that qualification and imple-
mentation of novel safety biomarkers into the main-
stream of the drug development process is only a 
small part of a much larger effort to modernise toxi-
cology and clinical safety. Nearly all of the biomarker 
qualification efforts that PSTC is involved with are 
directed at identifying drug-induced organ toxicity, a 
surrogate for histopathological evaluation in humans. 
However, what is truly needed is an integrated transla-
tional safety strategy that allows for a more predictive 
approach to assess clinical safety liabilities prior to 
introducing a new drug candidate for humans. Simply 
put, the application of toxicology in drug development 
needs to move from a descriptive science to a mecha-
nistic science. This will require a fundamental para-
digm shift and introduction of new experimental and 
data analysis approaches into safety assessment as 
well as the integration of information, traditionally 
viewed as non-safety data, into risk assessment. 
A vision of a possible translational strategy is out-
lined in Figure 3; we have called this approach tox-
icometrics. This vision also represents a general 
framework to support a systems pharmacology (toxi-
cology) approach that leverages in vitro and in vivo 
laboratory results, published data, and computational 
modelling to evaluate drug safety in order to enable a 
more predictive approach to translating safety infor-
mation from nonclinical species to humans. Clearly 
there is a need to better translate whole animal data to 
clinical trials, but it is likely that there will be areas of 
understanding that cannot be extrapolated from animal 
studies to humans. This gap can potentially be filled 
with appropriate in vitro tools and the construction of 
predictive computational tools that will require me-
chanistic input from these same in vitro tools. The 
objective of the outlined approach is to work toward 
the use of computational models in the systematic 
evaluation of safety data from clinical trials, and the 
integration of mechanistic modelling with current phar-
macokinetic/pharmacodynamics (PK/PD) approaches, 
physiologically-based pharmacokinetic modelling, and  
 
 
 
Figure 3. Vision for an integrated translational safety strategy. 
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mechanistic systems pharmacology approaches across 
multiple target organs. 
8. Conclusion 
In summary, there is a clear and critical need for the 
identification and regulatory qualification of improved 
safety biomarkers for the drug development process. 
C-Path’s PSTC consortium is a unique public-private 
partnership, bringing together pharmaceutical compa-
nies to share and validate safety testing methods under 
the advisement of worldwide regulatory agencies. The 
primary goal of PSTC is to qualify novel translational 
safety biomarkers for use in early clinical drug devel-
opment trials in order to enable safer investigation and 
development of new drug candidates. To this end, 
PSTC has established formal collaborations with 
FNIH BC KSP and IMI’s SAFE-T, two consortia with 
overlapping goals and members. In addition, PSTC 
has worked with regulatory authorities and piloted the 
Letter of Support approach to help facilitate the use of 
exploratory biomarkers. PSTC has successfully quali-
fied seven biomarkers of DIKI and received a Letter 
of Support for biomarkers of DIKI and drug-induced 
skeletal muscle injury. Ongoing efforts include ad-
vancing the qualification process, working with key 
stakeholders to define evidentiary standards for quali-
fication, and promoting and enabling a biomarker data 
repository. This includes the broader goal of defining 
an integrated translational safety strategy that utilises 
computational models to evaluate clinical trial data 
and the integration of mechanistic modelling with 
PK/PD and physiologically based pharmacokinetic 
modelling. With insufficient therapeutic index as a 
major cause of new drug candidate failure, ongoing 
science-based efforts to improve the continued effec-
tive collaboration of all stakeholders including regu-
latory agencies, pharmaceutical companies, govern-
ment research entities, academia, patient groups and 
non-profits organisations, will be utterly critical for 
realizing timely, transformative, science-based im-
provements in drug development.  
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